Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.61 |
| ▸ | MMP3 | P08254 | 4/20 | 0.61 |
| ▸ | MMP13 | P45452 | 3/20 | 0.61 |
| ▸ | MMP8 | P22894 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294057 | 0.92 | MMP1 (0.56) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL4292169 | 0.82 | MMP2 (0.67) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL1529242 | 0.81 | MMP2 (0.70) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL28762826 | 0.77 | KMT2A (0.49) | LMNAKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL7212133 | 0.76 | MMP1 (0.71) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL7208687 | 0.76 | MMP13 (1.00) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL4289945 | 0.74 | MMP2 (0.74) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL12020262 | 0.71 | MMP2 (0.69) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL28357379 | 0.70 | MMP13 (0.62) | MMP1MMP3MMP13MMP8MMP2 | |
| SCHEMBL12717370 | 0.70 | FFAR1 (0.56) | MMP1MMP3MMP13MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
| EP-2041142-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009416-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| US-7144917-B2 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006036928-A2 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | WAYNE STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1309579-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES | UNIV WAYNE STATE (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY | 2004-07-01 | — | — | US | disclosed |
| US-6703415-B2 | EPOXIDES OR THIIRANE DERIVATIVES; TREATING OR PREVENTING CANCER, ANGIOGENESIS, ARTHRITIS, CONNECTIVE TISSUE DISEASE, CARDIOVASCULAR DISEASE, INFLAMMATION OR AUTOIMMUNE DISEASE; ANTIFERTILITY AGENTS | WAYNE STATE UNIVERSITY | 2004-03-09 | — | — | US | disclosed |
| EP-1309579-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | UNITED STATES GOVERNMENT SECRETARY OF THE ARMY, THE | 2002-03-28 | — | — | US | disclosed |
| WO-2001092244-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | MMP12, MMP1, MMP3 | MMP1 2/4885MMP3 3/4885MMP13 8/4885 |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | MMP9, MMP10, MMP17 | MMP1 16/4885MMP3 5/4885MMP13 12/4885 |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | MMP1 1/4885MMP3 3/4885MMP13 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.